(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)
Health tech investors have been pouring money into early-stage startups as more mature companies with inflated pandemic-era price tags struggle to raise funds.
Series A health tech startups collected $1.7 billion in funding across 109 deals in the first half of this year, according to Silicon Valley Bank’s midyear report. That’s around $100 million more than the first half of last year. Median valuations for Series A deals also grew to $44 million, compared to $38 million in 2023.
Meanwhile, mid-stage Series B and Series C health tech startups are raising much smaller sums in extension rounds, Julie Ebert, Managing Director of SVB’s National Life Science and Healthcare team, told Endpoints News in an interview. The small boosts are meant to get the startups into the next year, so they could potentially
